Adherex Technologies (FENC)
(Delayed Data from NSDQ)
$5.57 USD
+0.04 (0.72%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $5.56 -0.01 (-0.18%) 7:58 PM ET
5-Strong Sell of 5 5
C Value A Growth B Momentum A VGM
Adherex Technologies Inc. (FENC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$15.50 | $22.00 | $13.00 | 180.29% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Adherex Technologies Inc. comes to $15.50. The forecasts range from a low of $13.00 to a high of $22.00. The average price target represents an increase of 180.29% from the last closing price of $5.53.
Analyst Price Targets (6 )
Broker Rating
Adherex Technologies Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, six are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/FENC.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/14/2024 | Craig-Hallum | Chase Knickerbocker | Strong Buy | Strong Buy |
8/13/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
8/13/2024 | Capital One Securities | Naureen Quibria | Strong Buy | Strong Buy |
8/7/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
3/28/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Strong Buy |
3/1/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 6 |
Average Target Price | $15.50 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.02 |